Nilotinib inhibits cell adhesion and monocyte activation.
(A) PCA plot of log 2-transformed LFQ intensities from THP-1 cells
pre-treated with DMSO, 5 μM nilotinib, or imatinib for 1 h before
stimulation with live E. coli for up
to 24 h, showing distinct grouping of treatments. (B,C) Volcano plot
of THP-1 cells treated with (B) nilotinib vs imatinib
and (C) nilotinib vsE. coli, a cutoff of FDR <0.05, and a 1.5-fold change between conditions.
(D) Expression levels of CD44, (E) CD11c, (F) CD14, (G) CD49a, and
(H) CD54 on the cell surface were measured by flow cytometry. (I)
Optical density of dissolved crystal violet was used to evaluate the
adhesion rate. Significant differences between two groups were determined
by the Mann–Whitney U-test. The statistical significance of
the comparisons with E. coli is indicated
as follows: ns, not significant; *, P ≤ 0.05;
**, P ≤ 0.01. Error bars represent the standard
deviation of four biological replicates.